
Phenibut HCl (β-phenyl-γ-aminobutyric acid hydrochloride) is a hydrophilic GABA derivative featuring a hydrochloride salt modification, which enhances solubility and stability in aqueous environments. The phenyl substitution allows for increased lipophilicity and receptor affinity, distinguishing it from native GABA.
This compound primarily interacts with GABA_B receptors, modulating neurotransmitter signaling pathways. It undergoes hepatic metabolism via deamination and conjugation, with renal clearance as the primary excretion route. The capsule formulation ensures precise dosing and controlled delivery for research applications.

Phenibut (β-phenyl-γ-aminobutyric acid) is a GABA derivative with a phenyl ring substitution, allowing for enhanced lipophilicity and bioavailability. As a free amino acid form, it maintains its unbound state, differing from its HCl or FAA counterparts in solubility and absorption properties.
This compound primarily interacts with GABA_B receptors, influencing neurotransmitter signaling pathways. It undergoes hepatic metabolism via deamination and conjugation, with primary excretion through renal clearance.

Phenibut HCl (β-phenyl-γ-aminobutyric acid hydrochloride) is a water-soluble GABA derivative with a hydrochloride salt modification, enhancing stability and dissolution in aqueous solutions. It features a phenyl ring substitution, which allows for improved lipophilicity and receptor interaction compared to native GABA.
This compound primarily interacts with GABA_B receptors, influencing neurotransmitter modulation and signal transduction. Phenibut HCl undergoes hepatic metabolism through deamination and conjugation, with renal clearance as the primary excretion pathway. The hydrochloride form exhibits higher solubility than its free amino acid counterpart, affecting absorption kinetics and bioavailability.